{"entity":{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","aka":[],"tldr":"A phase 2 trial of Brentuximab vedotin, Cyclophosphamide, Doxorubicin and Prednisone in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.","summary":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) is a phase 2 interventional study registered as NCT05673785 by Takeda, with 52 participants enrolled, started 2023-02-10 and due to reach its primary completion in 2025-04-27. Interventions recorded: Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05673785","url":"https://clinicaltrials.gov/study/NCT05673785"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy"],"targets":[],"drugs":["brentuximab-vedotin","cyclophosphamide","doxorubicin","prednisone"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05673785","phase":"2","setting":"A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","sponsor":"Takeda","started":"2023-02-10","startedType":"actual","yearReported":2026,"enrolled":52,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma","primary":true,"unit":"%","arms":[{"name":"Brentuximab Vedotin + CHP","n":52,"value":96.2,"note":"95% CI 86.8 to 99.5; Figures from the ClinicalTrials.gov results section (first posted 2026-06-12), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT05673785?tab=results"}]},"route":"/trials/nct05673785/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}